Description: Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre-clinical and Phase I/II clinical trials. Currently the Company is developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
Home Page: regenbiopharmainc.com
4700 Spring Street
La Mesa,
CA
91942
United States
Phone:
619 722 5505
Officers
| Name | Title |
|---|---|
| Dr. David Raymond Koos | Chairman, CEO, Pres, Sec. & Treasurer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 4.5964 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 1 |